NASDAQ$UTHR
United Therapeutics Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
United Therapeutics reported a revenue increase driven by growing patient use of medicines and progress in clinical trials.
United Therapeutics Corporation announced its Q3 2021 financial results, with total revenue growing 17% year over year to $444.7 million. The company is progressing with six phase 3 clinical trials across various forms of pulmonary hypertension and pulmonary fibrosis and continues to add new Tyvaso patients, reaching approximately 4,000 U.S. patients on Tyvaso therapy at the end of the third quarter.
- Total revenue increased by 17% year-over-year, reaching $444.7 million.
- Net income was $162.7 million, compared to $171.2 million in the third quarter of 2020.
- Non-GAAP earnings were $198.0 million, a 14% increase compared to $173.0 million in the third quarter of 2020.
- Approximately 4,000 U.S. patients on Tyvaso therapy at the end of the third quarter.
Headline financials
Revenue & EPS history
United Therapeutics · Revenue · Quarterly
$445M
Revenue by segment
United Therapeutics · $445M total across 5 segments · Q3 2021
- Nebulized Tyvaso$164M+26.8%36.9%
- Remodulin$125M+0.7%28.2%
- Orenitram$85.2M+14.1%19.2%
- Unituxin$55.3M+47.1%12.4%
- Adcirca$14.6M+5.8%3.3%
Forward guidance
The company provided forward-looking statements regarding revenue growth prospects, the goal of reaching 6,000 U.S. patients on Tyvaso by the end of 2022, expectations concerning the timing and success of efforts to obtain the necessary FDA approvals to launch Tyvaso DPI, research and development plans related to the PERFECT and TETON studies of Tyvaso, and the ADVANCE studies of ralinepag.
Tailwinds
- Revenue growth prospects
- Goal of reaching 6,000 U.S. patients on Tyvaso by the end of 2022
- Expectations concerning the timing and success of efforts to obtain the necessary FDA approvals to launch Tyvaso DPI
- Research and development plans related to the PERFECT and TETON studies of Tyvaso
- The ADVANCE studies of ralinepag
Headwinds
- Risk that we will not obtain the necessary FDA approvals to launch Tyvaso DPI
- Uncertainties related to clinical trial outcomes
- Dependence on regulatory approvals
- Competition in the market
- General economic conditions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+1.1%
Avg return
30 days after
57%
39 / 68 earnings
Positive
+16.2%
Q3 2022
Best reaction
-13.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -0.4% | -4.0% | |
| Q4 2025 | +13.1% | +8.5% | +10.4% | |
| Q3 2025 | +9.7% | +5.6% | +17.0% | |
| Q1 2025 | +0.8% | -0.7% | +6.0% | |
| Q4 2024 | -10.8% | -13.3% | -14.1% | |
| Q3 2024 | +6.0% | +6.8% | +5.0% | |
| Q2 2024 | -2.9% | -3.5% | +7.7% | |
| Q1 2024 | +10.2% | +11.2% | +17.4% | |
| Q4 2023 | +1.6% | +4.4% | +11.1% | |
| Q3 2023 | +2.4% | +2.4% | +8.0% | |
| Q2 2023 | -3.4% | -1.0% | -5.0% | |
| Q1 2023 | -5.7% | -8.0% | -5.1% | |
| Q4 2022 | -2.7% | -3.3% | -13.8% | |
| Q3 2022 | +16.2% | +16.8% | +22.0% | |
| Q2 2022 | -1.5% | -2.7% | -0.8% | |
| Q1 2022 | +4.1% | -0.6% | +27.2% | |
| Q4 2021 | -13.0% | -14.0% | -9.5% | |
| Q3 2021 | +4.8% | +5.1% | -3.2% | |
| Q2 2021 | +13.7% | +15.0% | +16.7% | |
| Q1 2021 | -1.7% | -2.8% | -9.9% | |
| Q4 2020 | -2.1% | -0.6% | -0.7% | |
| Q3 2020 | +5.6% | +8.6% | +9.8% | |
| Q2 2020 | +0.3% | +2.9% | -6.3% | |
| Q1 2020 | -0.2% | +2.0% | +7.5% | |
| Q4 2019 | -10.7% | -8.0% | -19.1% | |
| Q3 2019 | +3.3% | +3.6% | +6.1% | |
| Q2 2019 | +4.5% | -0.5% | +3.8% | |
| Q1 2019 | -1.3% | -1.9% | -18.1% | |
| Q4 2018 | +3.6% | -1.5% | -3.8% | |
| Q3 2018 | -6.2% | -6.2% | -3.7% | |
| Q2 2018 | +0.3% | +0.7% | +0.1% | |
| Q1 2018 | -8.3% | -8.3% | -4.2% | |
| Q4 2017 | -12.9% | -14.1% | -20.4% | |
| Q3 2017 | +0.2% | +0.8% | +5.1% | |
| Q2 2017 | -2.3% | -2.6% | -2.2% | |
| Q1 2017 | -1.0% | +1.0% | -2.2% | |
| Q4 2016 | -12.2% | -9.2% | -16.6% | |
| Q3 2016 | +4.5% | +6.0% | +19.0% | |
| Q2 2016 | +6.9% | +11.2% | +7.6% | |
| Q1 2016 | -10.6% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +8.8% | — | — | |
| Q2 2015 | +0.8% | — | — | |
| Q1 2015 | -4.4% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +2.7% | — | — | |
| Q1 2014 | +12.4% | — | — | |
| Q4 2013 | -4.1% | — | — | |
| Q3 2013 | +3.8% | — | — | |
| Q2 2013 | +2.7% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | +2.7% | — | — | |
| Q3 2012 | +2.9% | — | — | |
| Q2 2012 | +8.3% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | +8.0% | — | — | |
| Q2 2011 | +5.0% | — | — | |
| Q1 2010 | -5.3% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | +1.8% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q3 2009 | +8.0% | — | — | |
| Q3 2010 | +8.0% | — | — | |
| Q4 2009 | -8.2% | — | — | |
| Q2 2010 | -8.2% | — | — | |
| Q2 2009 | -8.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro